Local recurrence of malignant tumor of rectum (disorder)
ELECTRA
Year Started: 2022
ELECTRA is a feasibility trial to determine whether it is acceptable and feasible to recruit, randomise and deliver Intraoperative Electron Radiotherapy (IOERT) in a randomised controlled trial setting. Patients with locally advanced rectal cancer or locally recurrent rectal cancer involving the pelvic sidewall or posterior bony pelvis will be randomised to receive either extended margin surgery along, extended margin surgery with IOERT at standard dose (10 Gy), or extended margin surgery with IOERT at higher dose (15 Gy). Patients will be randomised to the three treatment arms in a 1:1:1 ratio. Patients will be followed up for a minimum of 12 months and up to 24 months following their surgery.
- Access:
- Data access only
- Type:
- Clinical Trial
- Status:
- Not-started
- Consent restrictions:
- Commercial restriction, DNA restriction, Other animal work restriction, Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Clinical records | > 6 months |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| There are no material preservation details for this sample set | |||||
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| There are no material preservation details for this sample set | |||||
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| There are no material preservation details for this sample set | |||||
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| There are no material preservation details for this sample set | |||||
Local recurrence of malignant tumor of cervix (disorder)
CRAIN
Year Started: 2022
A phase 1b TiTE-CRM dose escalation clinical trial of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Not-started
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Pathology records | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Affected | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| DNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Affected | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| DNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Diffuse non-Hodgkin's lymphoma (disorder)
Pola-R-ICE-polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) vs R-ICE in patients with primary refractory or relapsed DLBCL
Year Started: 2022
tissue specimen, serum, plasma,
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Not-started
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Clinical records | > 6 months |
| Genomic datasets | > 6 months |
| Imaging data | > 6 months |
| National registries | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |